Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Exogenous Melatonin in Postmenopausal Women with Insomnia
NCT05440734 · Douglas Mental Health University Institute · NA · terminated · last registry update 2025-02-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of funding” | – | Registry record, Douglas Mental Health University Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-04Results posted on the registry: M.D. Anderson Cancer Center, Methylphenidate Hydrochloride + Therapeutic Melatonin (NCT01628029)
- 2026-01-13Phase 3 first posted: Emory University, Zolpidem (NCT07336277)
- 2026-01-13Phase 3 first posted: Ain Shams University, Melatonin group + Midazolam group (NCT07336095)
- 2025-12-24Also stopped (withdrawn): University of Colorado, Denver, a drug against MTNR1A (NCT06292000)
- 2025-10-14Results posted on the registry: Brigham and Women's Hospital, a drug against MTNR1A (NCT04868539)
- 2025-10-09Also stopped (terminated): Brigham and Women's Hospital, Tasimelteon (NCT05922995)
- 2025-08-29Results posted on the registry: National Taiwan University Hospital, Melatonin + Placebo (NCT05439876)
- 2025-08-20Results posted on the registry: Oregon Health and Science University, melatonin (NCT04932096)
- 2025-08-13Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, a drug against MTNR1A (NCT07120880)
- 2025-05-04Results posted on the registry: NYU Langone Health, Melatonin 5 mg (NCT04795336)
- 2025-05-01Phase 3 first posted: Vanda Pharmaceuticals, Tasimelteon Oral Suspension + Placebo (NCT06953869)
- 2025-04-20Phase 3 first posted: Tanta University, Dexmedetomidine + Melatonin (NCT06935292)
- 2025-04-11Also stopped (withdrawn): Stanford University, Melatonin 5 mg + Placebo Oral Tablet (NCT03879707)
- 2025-03-05Phase 3 first posted: Bart Koes, Melatonin 10 mg + Placebo (NCT06859957)
- 2025-02-27Results posted on the registry: Providence Health & Services, 3 mg Melatonin + 5 mg Melatonin (NCT03498131)
- 2025-02-25Phase 3 first posted: Tanta University, Melatonin 10 MG + Placebo (NCT06846086)
- 2025-02-05Phase 3 first posted: Mohsen Pourazizi, melatonin 3mg + Placebo Drug (NCT06809751)
- 2025-01-24Results posted on the registry: University of Jordan, Placebo + Diazepam (NCT06103188)
- 2024-12-05Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, olanzapine and melatonin (NCT00512070)
- 2024-11-22Phase 3 first posted: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT06701396)
- 2024-11-12Phase 3 first posted: Ain Shams University, Melatonin (NCT06685679)
- 2024-09-03Also stopped (withdrawn): University of Nebraska, Melatonin + Diphenhydramine (NCT03688464)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-22Results posted on the registry: Northwell Health, a drug against MTNR1A (NCT05349188)
- 2024-07-22Phase 3 first posted: Nanjing Chia-tai Tianqing Pharmaceutical, Ramelteon + Ramelteon placebo (NCT06512363)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision